Drug Approval | November 24, 2025
Alvotech and Advanz Pharma secure European nod for Gobivaz, first biosimilar to Simponi
Gobivaz is authorised for adults with rheumatoid arthritis (in combination with methotrexate), psoriatic arthritis (with or without methotrexate), axial spondyloarthritis, and ulcerative colitis
